Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to predict relapse in common blood vessel disease

NCT ID NCT07246577

Knowledge-focused Sponsor: Vastra Gotaland Region Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking for 340 people with suspected giant cell arteritis (GCA), a condition that causes inflammation in blood vessels and is usually treated with long-term steroids. The goal is to find better ways to predict who will have relapses and to monitor the disease using ultrasound and blood tests. By improving these tools, doctors hope to personalize treatment and reduce side effects from steroids.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 340 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A new cohort will be recruited. Individuals presenting with suspected GCA at Sahlgrenska University Hospital in Gothenburg, Sweden, or at Skaraborg Hospital Skövde, Sweden, will be invited to participate in the study. Diagnostic ultrasound examinations and follow-up assessments will be conducted at Sahlgrenska University Hospital in Gothenburg. After study enrollment, participants diagnosed with GCA will be followed for 12 months, with scheduled visits at 1, 6, and 12 months after initiation of treatment. If clinical relapse of GCA is suspected outside of the scheduled visits, an additional examination will be performed. Participants who are not diagnosed with GCA will be followed up by telephone after 6 months to confirm diagnostic status.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Individuals referred for evaluation due to suspected giant cell arteritis (GCA). * Ability to provide written informed consent. Exclusion Criteria * Previous diagnosis of GCA. * Previous temporal artery biopsy performed as part of prior GCA evaluation. * Treatment with high-dose corticosteroids (\>7.5 mg/day) for more than two weeks before initiation of the diagnostic work-up. * Inability to provide informed consent. * Inability to comply with the study protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Giant cell arteritis (GCA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Giant Cell Arteritis temporal arteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Giant cell arteritis (GCA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sahlgrenska Universitetssjukhuset

    RECRUITING

    Gothenburg, 41345, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.